北海康成(01228) - 2025 - 年度业绩

Overview of 2024 Annual Report Supplemental Announcement This announcement supplements CANbridge Pharmaceuticals Inc.'s 2024 annual report, detailing asset write-offs and share schemes - This announcement supplements CANbridge Pharmaceuticals Inc.'s 2024 annual report, providing additional information on right-of-use asset write-offs and share schemes[2][3] Write-off of Right-of-Use Assets The company disclosed write-offs of U.S. right-of-use assets due to business scaling, recognizing lease liabilities at year-end - The company negotiated with the landlord of its U.S. Boston office and laboratory due to a U.S. scaling-down plan and vacated in the second half of 2024[4] - The company began defaulting on rent in August 2024[4] - Despite vacating, the lease agreement remained legally binding as of December 31, 2024, until the termination agreement became effective on February 8, 2025, thus lease liabilities were recognized at carrying value and not derecognized or reassessed[4] Details of Share Schemes Supplementary details were provided for pre-IPO and post-IPO share schemes, covering exercise, vesting, grants, limits, and a disclosure clarification - Supplementary information pertains to the pre-IPO equity incentive scheme, post-IPO restricted share unit scheme, and post-IPO share option scheme[5] Exercise and Vesting of Share Incentives During the Reporting Period The company disclosed pre-IPO share option exercises and post-IPO restricted share unit vesting for employees and Dr. Xue Overview of Share Incentive Exercise and Vesting During the Reporting Period | Share Scheme | Participant | Number of Shares | Exercise or Vesting Date | Weighted Average Closing Price Immediately Preceding Date (HKD) | | :--- | :--- | :--- | :--- | :--- | | Pre-IPO Equity Incentive Scheme | Certain Employees | 276,200 | 2023年12月29日 - 2024年1月23日 | 0.87 | | Post-IPO Restricted Share Unit Scheme | Dr. Xue | 75,000 | 2024年1月12日 - 2024年12月12日 | 0.36 | | Post-IPO Restricted Share Unit Scheme | Other Employees | 459,375 | 2024年1月12日 - 2024年11月12日 | 0.30 | Grant and Grantable Limits of Share Schemes The company granted 19.15 million share incentives (4.51% of issued shares) and disclosed scheme grantable limits - During the reporting period, 6,336,000 restricted share units were granted under the post-IPO restricted share unit scheme, and 12,815,000 share options were granted under the post-IPO share option scheme[6] - The total number of restricted share units and share options granted during the reporting period was 19,151,000 shares, representing approximately 4.51% of the weighted average number of relevant class of shares issued during the same period[6] Grantable Limits of Share Schemes as of 2024 Annual Report Date | Share Scheme | Maximum Number of Shares Grantable | Approximate Percentage of Total Issued Shares | | :--- | :--- | :--- | | Post-IPO Restricted Share Unit Scheme (Total) | 42,483,832 | 10% | | Post-IPO Restricted Share Unit Scheme (Service Providers) | 4,248,383 | 1% | | Post-IPO Share Option Scheme (Total) | 42,483,832 | 10% | | Post-IPO Share Option Scheme (Service Providers) | 4,248,383 | 1% | Clarification of 2024 Annual Report Disclosure The company clarified a 2024 annual report error regarding restricted share unit disclosure, stating 'exercise' is inapplicable - Clarification that the column 'Number of relevant shares of restricted share units exercised during the reporting period' in the 2024 annual report, page 46 table, is not applicable to restricted share units and should be deleted[6] - The total number of relevant shares for restricted share units during the reporting period was 534,375 shares[6] Concluding Remarks of the Announcement This supplemental announcement provides additional information, with all other 2024 annual report content unchanged - This supplementary information does not affect other information contained in the 2024 annual report, and all other information remains unchanged[7] - Board members include Executive Director Dr. Xue Qun, Non-executive Directors Ms. Zhao Wei and Mr. Wang Tingwei, and Independent Non-executive Directors Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Chen Bingjun, and Dr. Hu Lan[8]